Please add new claims 21-25, as follows:

21. (New) The method according to claim 11, wherein the PTH receptor or PTHrP receptor is a PTH/PTHrP type I receptor.

22. (New) The method according to claim 11, wherein the substance that binds to a ligand of PTH receptor or PTHrP receptor to inhibit binding between the ligand and the receptor is chosen from at least one of an anti-PTHrP antibody and an anti-PTH antibody.

23. (New) The method according to claim 4, wherein the syndrome associated with malignancy is at least one of decreased body weight, decreased food consumption, or decreased water consumption.

24. (New) The method according to claim 7, wherein the central nervous system disease is a movement disorder.

25. (New) The method according to claim 11, wherein the disease mediated by PTH- or PTHrP-cytokine cascade is septicemia.

REMARKS

Applicants have amended claims 1-20. Applicants have added new claims 21-25 to more particularly point out and distinctly claim the invention. Claims 1-25 are pending. The new claims find support in the claims as originally filed and throughout the specification, and thus no new matter has been added. Examples of support for the new claims are shown in the table below.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202 408 4000
Fax 202 408 4400
www.finnegan.com

NEW CLAIM	SUPPORT
21	Original claim 14
22	Original claim 15
23	Example 3; page 29 line 24 to page 31, line 2
24	Example 4; page 31 line 4 to page 32, line 9
25	Example 2; page 29 line 19 to page 29, line 22

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: November 7, 2002

By: Rebecca M. McNeill

Rebecca M. McNeill
Reg. No. 43,796

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

APPENDIX TO THE AMENDMENT

1. (Twice Amended) A ~~therapeutic agent for~~ method of treating or preventing a disease ~~caused~~ mediated by PTH or PTHrP comprising administering to a patient at least one ~~an~~ active ingredient chosen from

a) an agonist or antagonist of binding to a PTH receptor or PTHrP receptor, and

b) a substance that binds to a ligand of either receptor to promote or inhibit binding between the ligand and the receptor.

2. (Twice Amended) The ~~therapeutic agent~~ method according to claim 1, wherein the disease ~~caused~~ mediated by PTH or PTHrP is a disease other than hypercalcemia.

3. (Twice Amended) The ~~therapeutic agent~~ method of claim 1, wherein the ~~therapeutic agent is a QOL improving agent for alleviating a symptom of a~~ disease ~~caused~~ mediated by PTH or PTHrP reduces the QOL of at least one patient.

4. (Twice Amended) The ~~therapeutic agent~~ method of claim 1, wherein the ~~therapeutic agent~~ disease is ~~for~~ a syndrome associated with malignancy ~~caused~~ and the syndrome is mediated by PTHrP.

5. (Twice Amended) The ~~therapeutic agent~~ method according to claim 4, wherein the syndrome associated with malignancy is chosen from at least one of digestive system disorders, proteometabolism abnormality, saccharometabolism

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

[illegible] Street, NW
Washington, DC 20005
202 408 4000
Fax 202 408 4400
www.finnegan.com

abnormality, lipid metabolism abnormality, anorexia, hematological abnormality, electrolyte abnormality, immunodeficiency and pain.

6. (Twice Amended) The ~~therapeutic agent~~ method according to claim 1, wherein the disease is chosen from at least one of

a) ~~a~~ secondary hyperparathyroidism ~~caused by PTH~~ and

b) ~~a~~ primary hyperparathyroidism ~~caused by PTH~~.

7. (Twice Amended) The ~~therapeutic agent~~ method of claim 1, wherein the ~~therapeutic agent~~ disease is ~~for~~ at least one central nervous system disease ~~caused~~ mediated by PTH or PTHrP.

8. (Twice Amended) The ~~therapeutic agent~~ method according to claim 7, wherein the central nervous system disease is chosen from at least one of dyssomnia, neuropathy, nervous symptom disorder, brain metabolism abnormality, cerebral circulation abnormality, autonomic imbalance, and endocrine system abnormality with which the central nervous system is associated.

9. (Twice Amended) The ~~therapeutic agent~~ method of claim 1, wherein the ~~therapeutic agent is for a~~ disease is ~~caused~~ mediated by PTH- or PTHrP-cytokine cascade.

10. (Twice Amended) The ~~therapeutic agent~~ method according to claim 9, wherein the cytokine is chosen from at least one of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL- 15, G-CSF, GM-CSF, M-CSF, EPO, LIF, TPO, EGF, TGF-α, TGF-β, FGF, IGF, HGF, VEGF, NGF, activin, inhibin, a BMP family member, TNF and IFN.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street NW
Washington DC 20005
202 408 4000
Fax 202 408 4400
www.finnegan.com

11. (Twice Amended) The ~~therapeutic agent~~ method according to claim 9 or 10, wherein the disease ~~caused~~ mediated by PTH- or PTHrP-cytokine cascade is chosen from at least one of septicemia, cachexia, inflammation, hemopathy, calcium metabolism abnormality, and autoimmune disease.

12. (Twice Amended) The ~~therapeutic agent~~ method of claim 1, wherein the ~~therapeutic agent~~ active ingredient is a central nervous system regulator.

13. (Twice Amended) The ~~therapeutic agent~~ method of claim 1, wherein the ~~therapeutic agent~~ active ingredient is a cytokine network regulator.

14. (Amended) The ~~agent~~ method according to any one of claims 1 to 10 or 12 to 13, wherein the PTH receptor or PTHrP receptor is a PTH/PTHrP type I receptor.

15. (Twice Amended) The ~~agent~~ method according to any one of claims 1 to 10 or 12 to 13, wherein the substance that binds to a ligand of PTH receptor or PTHrP receptor to inhibit binding between the ligand and the receptor is chosen from at least one of an anti-PTHrP antibody and an anti-PTH antibody.

16. (Twice Amended) The ~~agent~~ method according to claim 15, wherein the substance that binds to a ligand of PTH receptor or PTHrP receptor to inhibit binding between the ligand and the receptor is an anti-PTHrP antibody.

17. (Amended) The ~~agent~~ method according to claim 16, wherein the anti-PTHrP antibody is a humanized anti-PTHrP antibody.

18. (Amended) The ~~therapeutic agent~~ method according to claim 2, wherein the disease is ~~selected~~ chosen from at least one of

a) ~~a~~ secondary hyperparathyroidism ~~caused by PTH~~ and

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street NW
Washington DC 20005
202 408 4000
Fax 202 408 4400
www.finnegan.com

b) ~~a~~ primary hyperparathyroidism ~~caused by PTH~~.

19. (Amended) The ~~therapeutic agent~~ method according to claim 10, wherein the disease ~~caused~~ mediated by PTH or PTHrP-cytokine cascade is chosen from at least one of septicemia, cachexia, inflammation, hemopathy, calcium metabolism abnormality, and autoimmune disease.

20. (Amended) The ~~agent~~ method according to claim 14, wherein the substance that binds to a ligand of PTH receptor or PTHrP receptor to inhibit binding between the ligand and the receptor is chosen from at least one of an anti-PTHrP antibody and an anti-PTH antibody.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street NW
Washington DC 20005
202 408 4000
Fax 202 408 4400
www.finnegan.com